Specnuezhenide Alleviates Senile Osteoporosis by Activating TGR5/FXR Signaling in Bone Marrow Mesenchymal Stem Cells and RANKL-Induced Osteoclasts
Drug Design, Development and Therapy · 2025-03 · Volume 19 · 1595-1608
DOI: 10.2147/dddt.s493711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-03. Verfasst von Xuehui Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Osteoporosis, Osteoclasts, RANK Ligand. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background: , an herb prescribed for the treatment of senile osteoporosis. However, the direct role of SPN on bone metabolism remains unclear. In this study, the effects of SPN on d-galactose (d-gal)-induced mice, bone marrow mesenchymal stem cells (BMSCs), and nuclear factor-κB ligand-induced osteoclasts were examined.
Methods
Micro-computed tomography was used to observe the bone microstructure. Osteogenesis was examined using Western blotting and alkaline phosphatase staining. Osteoclastogenesis was examined using Western blotting and F-actin ring staining. Senescence-associated β-galactosidase was used to detect cell senescence. In addition, the expression of Takeda G protein-coupled receptor 5 (TGR5)/farnesoid X receptor (FXR) signaling pathway-related genes and proteins was determined through quantitative real-time polymerase chain reaction and immunofluorescence.
Results
Oral administration of SPN improved the bone microstructure in d-gal-induced mice and increased bone mineral density, bone volume, trabecular thickness, and trabecular number. SPN also upregulated the expression of the osteogenesis markers osteocalcin, bone morphogenetic protein 2, and runt-related transcription factor 2 and downregulated the expression of the osteoclasis markers tartrate-resistant acid phosphatase, nuclear factor-κB, and nuclear factor of activated T-cells in the d-gal-induced bone. Furthermore, SPN increased alkaline phosphatase staining, inhibited F-actin ring formation, and reduced the activity of senescence-associated β-galactosidase in vitro. Mechanistically, SPN activated the TGR5/FXR pathway in d-gal-induced BMSCs and osteoclasts. The protective effects of SPN were abolished after addition of the TGR5 inhibitor SBI-115 or FXR inhibitor DY268. Moreover, SPN could elevate the protein and mRNA levels of TGR5, FXR, and the downstream small heterodimer partner in d-gal-induced bone.
Conclusion
SPN alleviated senile osteoporosis and cell senescence by activating the TGR5/FXR pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, People's Republic of China.
- School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Zitieren
APA
Deng, X., Lin, B., Xiao, W., Wang, F., Xu, P., & Wang, N. (2025). Specnuezhenide Alleviates Senile Osteoporosis by Activating TGR5/FXR Signaling in Bone Marrow Mesenchymal Stem Cells and RANKL-Induced Osteoclasts. Drug Design, Development and Therapy, Volume 19, 1595-1608. https://doi.org/10.2147/dddt.s493711
Vancouver
Deng X, Lin B, Xiao W, Wang F, Xu P, Wang N. Specnuezhenide Alleviates Senile Osteoporosis by Activating TGR5/FXR Signaling in Bone Marrow Mesenchymal Stem Cells and RANKL-Induced Osteoclasts. Drug Design, Development and Therapy. 2025;Volume 19:1595-1608. doi:10.2147/dddt.s493711
BibTeX
@article{Deng2025,
author = {Deng, Xuehui and Lin, Bingfeng and Xiao, Wenlong and Wang, Fang and Xu, Pingcui and Wang, Nani},
title = {Specnuezhenide Alleviates Senile Osteoporosis by Activating TGR5/FXR Signaling in Bone Marrow Mesenchymal Stem Cells and RANKL-Induced Osteoclasts},
journal = {Drug Design, Development and Therapy},
year = {2025},
volume = {Volume 19},
pages = {1595--1608},
doi = {10.2147/dddt.s493711}
}
EUVIMED